About BCL2/adenovirus E1B 19 kDa protein-interacting protein 3-like
BCL2/adenovirus E1B 19 kDa protein-interacting protein 3-like (BNIP3L) is a protein
from Homo sapiens identified by UniProt accession
O60238, 219 residues long.
MolForge cross-references it against 0 known binders and
404 disease associations.
Target properties
| Protein name | BCL2/adenovirus E1B 19 kDa protein-interacting protein 3-like |
|---|
| UniProt accession | O60238 |
|---|
| Gene | BNIP3L |
|---|
| Organism | Homo sapiens |
|---|
| Length | 219 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (404)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.44
- Red cell distribution width · score 0.36
- erythrocyte count · score 0.34
- mean corpuscular hemoglobin concentration · score 0.33
- mean corpuscular volume · score 0.32
- reticulocyte count · score 0.32
- schizophrenia · score 0.32
- mean corpuscular hemoglobin · score 0.30
- self reported educational attainment · score 0.30
- red blood cell density measurement · score 0.29
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-O60238-F1 | alphafold | PREDICTED | 60.42 | — |
Amino-acid sequence (219 residues)
MSSHLVEPPP PLHNNNNNCE ENEQSLPPPA GLNSSWVELP MNSSNGNDNG NGKNGGLEHV PSSSSIHNGD MEKILLDAQH ESGQSSSRGS SHCDSPSPQE DGQIMFDVEM HTSRDHSSQS EEEVVEGEKE VEALKKSADW VSDWSSRPEN IPPKEFHFRH PKRSVSLSMR KSGAMKKGGI FSAEFLKVFI PSLFLSHVLA LGLGIYIGKR LSTPSASTY
Explore BCL2/adenovirus E1B 19 kDa protein-interacting protein 3-like with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets